Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer Meeting Abstract
| Authors: | Soria, J.; Sequist, L. V.; Goldman, J. W.; Wakelee, H. A.; Gadgeel, S. M.; Varga, A.; Yu, H. A.; Solomon, B. J.; Ou, S. H.; Papadimitrakopoulou, V.; Oxnard, G. R.; Horn, L.; Dziadziuszko, R.; Chao, B.; Spira, A. I.; Liu, S.; Mekhail, T.; Matheny, S.; Litten, J.; Camidge, R. D. |
| Abstract Title: | Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer |
| Meeting Title: | 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 50 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2014 Nov 18-21 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2014-11-01 |
| Start Page: | 199 |
| Language: | English |
| ACCESSION: | WOS:000347755700606 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(14)70731-2 |
| Notes: | Meeting Abstract: 10LBA -- 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics -- NOV 18-21, 2014 -- Barcelona, SPAIN -- Source: Wos |
